EMSAM
LOE Approachingselegiline
NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
EMSAM (selegiline) is monoamine oxidase inhibitors [moa]. First approved in 2006.
Drug data last refreshed 18h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMSAM is a transdermal extended-release formulation of selegiline, a monoamine oxidase inhibitor (MAOI) indicated for major depressive disorder. It works by inhibiting the breakdown of neurotransmitters (dopamine, norepinephrine, serotonin) in the central nervous system. The transdermal route provides steady-state delivery and improved tolerability compared to oral MAOI formulations.
$12MPart D
LOE ApproachingDeclining
EMSAM is in late-stage market maturity with modest Medicare claims (5,360 in 2023), indicating a niche product facing significant competitive pressure and approaching loss of exclusivity.
Mechanism of Action
Monoamine Oxidase Inhibitors
Pharmacologic Class:
Monoamine Oxidase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Started Mar 2007
77 enrolled
Parkinson's Disease
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
127 enrolled
Cognition DisordersHIV Infections
Career Relevance
EMSAM offers limited career growth opportunities given its approaching LOE, niche market position (5,360 annual claims), and declining competitive relevance. Roles on this product are typically in maintenance-focused commercial teams managing a legacy asset rather than growth-oriented initiatives.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.